| Trial ID | NCT07340554 |
| Status | Recruiting |
| Condition | Cannabis Use |
| Intervention | Contingency Management |
This trial addresses a critical gap in adolescent cannabis treatment by investigating neurobiological predictors of treatment response. Understanding brain-based markers that predict which teens will benefit most from contingency management could enable personalized treatment approaches during this vulnerable developmental period.
This observational study enrolls teens aged 14-17 who use cannabis and employs neuroimaging to examine brain activity patterns related to learning and reward processing. Participants undergo fMRI scanning before entering a 10-week virtual contingency management program that provides incentives for cannabis abstinence, verified through home-based urine testing. The primary endpoint is identifying neural predictors of treatment response, while secondary measures include cannabis use reduction and sustained abstinence rates.
“If this research identifies reliable neuroimaging biomarkers, I could potentially use brain-based assessments to guide treatment selection for adolescent patients, moving beyond trial-and-error approaches to more precise, individualized care strategies.”
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What do the brain scans in this adolescent cannabis trial examine?
Participants undergo fMRI scanning, a type of neuroimaging, before entering the treatment program. The scans examine brain activity patterns related to learning and reward processing. These scans allow researchers to look for brain-based patterns linked to how each teen later responds to treatment.
Who can take part in this adolescent cannabis treatment study?
The study enrolls teens aged 14 to 17 who use cannabis. It is an observational study registered as NCT07340554 and is listed as recruiting. The summary does not describe other eligibility requirements beyond age and cannabis use.
What is the contingency management program in this trial?
It is a 10-week virtual program that provides incentives for cannabis abstinence. Abstinence is verified through home-based urine testing. Teens enter the program after completing fMRI scanning, so researchers can later compare their brain activity with how they respond to treatment.
What outcomes will this adolescent cannabis trial measure?
The primary endpoint is identifying neural predictors of treatment response. Secondary measures include reduction in cannabis use and rates of sustained abstinence. Together, these outcomes connect the brain imaging findings to how well teens do in the contingency management program.
Get the next evidence review in your inbox
Plain-language summaries of the newest cannabis research, written by a physician. Free to read, and you can unsubscribe at any time.
Join the growing cannabis community. Free. One-click subscribe. Delivered by Substack.
